PPARG and familial pancreatic carcinoma: In addition totheir antiproliferative actions, both ligands, 15-PGJ2 and ciglitazone, reducedthe invasive capacity of pancreatic cancer cells in vitro by a PPAR-γ-mediated decrease of urokinase-typeplasminogen activator and elevation of plasminogen activator inhibitor-1 expressionthat resulted in an overall reduction in urokinase activity [41].